AtaiBeckley Inc (ATAI)

This might be making a DRUG move if acquired by big pharma.

Yup. Something is up...

Is everybody ready? ... I think the time is Finally upon us for the big Partnership announcement!!

We're definitely getting close and I'm predicting a bidding war!

Is everybody ready? ... I think the time is Finally upon us for the big Partnership announcement!!

We're definitely getting close and I'm predicting a bidding war!

AtaiBeckley is speculated to have received takeover interest - report

https://stocks.apple.com/AE1Jp1ybkS8qtURMNnu-Sxg

AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder
July 6, 2026

https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-doses-last-patient-vls-01-phase-2b-trd-study-plans

156 patients randomized in multi-center, double-blind, placebo-controlled Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830)
AtaiBeckley plans to advance VLS-01 into major depressive disorder (MDD) in Phase 3, with generalized anxiety disorder (GAD) as a potential follow-on indication
VLS-01 and BPL-003 (in Phase 3 development for treatment-resistant depression with Breakthrough Therapy Designation) together positioned to address patients across the spectrum of mood and anxiety disorders

GW Pharmaceuticals / Epidiolex is the pathway precedent people should be studying with respect to psychedelic biotech.

Jazz Pharmaceuticals acquired GW Pharmaceuticals for approximately $7.2 billion.

Why does that matter for psychedelic biotech?

Because GWPH proved that a controlled-substance-related drug can move through the normal pharmaceutical pathway:

Clinical trials > FDA approval > DEA scheduling action > prescription commercialization > big pharma acquisition.

Epidiolex was a purified CBD prescription medicine derived from cannabis. Cannabis itself did not need to become federally legal for Epidiolex to become an FDA-approved prescription drug. The government did not legalize the whole plant. It approved and scheduled a specific medical product.

That is the key point for DFTX, CMPS, and ATAI.

If Definium’s DT120, Compass’s COMP360, or ATAI/AtaiBeckley’s pipeline drugs make it through FDA review, the government does not need to broadly legalize LSD, psilocybin, DMT, or other psychedelics. It can approve and schedule the specific prescription drug product, for the specific indication, under specific medical controls.

That is the same logic Epidiolex followed.

And the valuation precedent is real. Jazz paid roughly $7.2B for GWPH. At the time, Epidiolex had already exceeded $500M in annual sales and was viewed as having blockbuster potential. By 2025, Epidiolex/Epidyolex had reached about $1.1B in annual net sales.

That is why the psychedelic NDA pathway is so important.

DFTX is not trying to legalize LSD broadly. It is trying to turn DT120 into an FDA-approved psychiatric medicine for MDD, GAD, and potentially PTSD.

CMPS is not trying to legalize mushrooms. It is trying to turn COMP360 into an FDA-approved treatment for TRD, with PTSD expansion potential.

ATAI is earlier, but the same logic could apply if BPL-003, VLS-01, or EMP-01 succeeds.

If these companies can create approved CNS drug franchises with $1B, $2B, $3B+ in peak annual sales, then the GWPH/Jazz precedent shows why multi-billion-dollar valuations are possible.

The government does not need to legalize the entire substance to approve and reschedule a specific prescription drug.

That is the part of the story I think the market is still digesting.

Big $5M chunk right there. Nice buy to whoever took that. BIG MONEY ROLLING.

H.R.9559 - To accelerate the development of, and access to, psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the United States, and for other purposes.

https://www.congress.gov/bill/119th-congress/house-bill/9559

Helps with DEA rescheduling visibility, manufacturing quotas, controlled distribution, clinical site expansion, VA-related treatment pathways, and broader institutional comfort around psychedelic medicine.

This is also the kind of policy shift that big pharma pays attention to. A late-stage drug with strong data is one thing. A late-stage drug with improving federal policy, potential priority voucher support, and clearer post-approval scheduling rules is much easier to underwrite.

Bullish for the whole sector.

Psychedelics iPhone moment

The 3 horses are identified.

Others will succeed too, but these three are the unicorns and I suspect they will reach a combined market cap of 80-100B by H2 2027.

Currently they sit at 10B combined. That is a 8-10X from these levels. Ready?

Better Sex, Better Hair, Better Sleep: ‘Humanmaxxing’ Is Here - New York Times

https://www.nytimes.com/2026/06/11/opinion/biotech-maxxing-christian-angermayer.html

The biotech billionaire who wants to rebuild your body and blow your mind.

To be honest it will start happening for all 3 within the next week or two. $ATAI $DFTX and $CMPS... all three are unicorns!

Bidding war should begin soon! 😎👍

nice to hear

(ATAI)... HC Wainwright & Co. -- Price Target Maintained at $25

buying!!!

about to pass 5.00.

Is this finally the breakthrough moment for psychedelic therapies?

https://www.rbccm.com/en/insights/2026/05/is-this-finally-the-breakthrough-moment-for-psychedelic-therapies

Psychedelics may finally be close to mainstream medical use, but is the healthcare system prepared for mass delivery to patients?

Hosted By Joseph Coletti
Featuring Brian Abrahams and Leonid Timashev
Published May 22, 2026

Key points

Patient and physician interest and favorable regulation signal an imminent breakthrough for psychedelics to treat mental ill-health.

April’s Presidential order on accelerated research and access for veterans with PTSD is also supportive.

Psychedelics raise challenges for clinical trials, but companies are finding ways to overcome these.

RBC’s research indicates existing clinic infrastructure is equipped to deliver psychedelics with the required clinical supervision.

Awesome day here!

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-reports-first-quarter-2026-financial-results-and

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026
VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026

Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder

Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029

PANEL: Clinical Risk, Regulatory Reality and the Path to Scale - Needham Virtual Psychedelics Forum

$DFTX $ATAI $CMPS

https://event.summitcast.com/view/HTrbmKNKd3jrHMB6knVrhU/guest_book?session_id=nXqi2QwF47Ftq7xFM8Bt5j

$ATAI DemeRx Announces FDA Acceptance of IND Application to Advance DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)

https://www.businesswire.com/news/home/20260422651767/en/DemeRx-Announces-FDA-Acceptance-of-IND-Application-to-Advance-DMX-1001-for-the-Treatment-of-Alcohol-Use-Disorder-AUD

this should bode well for ATAI

Apeiron’s Christian Angermayer on using psychedelic drugs for mental health treatment

https://www.cnbc.com/video/2026/04/22/apeirons-christian-angermayer-on-using-psychedelic-drugs-for-mental-health-treatment.html?__source=sharebar|twitter&par=sharebar

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder

April 22, 2026
PDF Version

EMP-01 demonstrated a large, clinically meaningful reduction in patient-reported SAD symptoms at Day 43: placebo-adjusted LSMD -11.5 points (p=0.002) on SPIN; placebo-adjusted LSMD -15.6 points (p=0.004) on SAFE - a 38% and 32% reduction, respectively
Patient-perceived global improvement: 49% PGI-C responders at Day 43 compared to 12% on placebo
No severe or serious adverse events

https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-announces-additional-phase-2a-results-emp-01-oral-r

Unreal!

Volume Pre-market here is out of control!

Closes above 5.25 today easy!

This is it... Monday AM firework show.

ABC News - Trump signs executive order to accelerate research of psychedelic-based drugs

Interview with Martin MaKary

Couldn't agree more. This is it!

Absolutely beautiful and long overdue.  Just saying .  Vets need help

$ATAI Psychedelics Executive Order — News Coverage Roundup
The Washington Post Trump orders more access to psychedelics like LSD, psilocybin and ibogaine https://www.washingtonpost.com/politics/2026/04/17/trump-psychedelics-psylocibin-research/
Pittsburgh Post-Gazette Trump signs order to speed review of psychedelics, including the controversial drug ibogaine https://www.post-gazette.com/news/politics-nation/2026/04/18/trump-psychedelics-drugs-ibogaine-veterans/stories/202604180045
WSAZ President Trump signs executive order encouraging research on psychedelic drugs https://www.wsaz.com/2026/04/18/president-trump-signs-executive-order-encouraging-research-psychedelic-drugs/
CNN Trump accelerates research on psychedelic treatments and asks, ‘Can I have some?’ https://www.cnn.com/2026/04/18/politics/trump-signs-executive-order-urging-more-research-into-psychedelic-ibogaine
MS NOW Trump signs executive order on psychedelic drugs — with Joe Rogan by his side https://www.ms.now/news/trump-executive-order-psychedelic-drugs-joe-rogan
The Guardian Trump announces reforms to accelerate access to psychedelic drug treatments https://www.theguardian.com/us-news/2026/apr/18/trump-psychedelic-drugs-executive-order
USA Today Trump signs order pushing psychedelics research after Joe Rogan call https://www.usatoday.com/story/news/politics/2026/04/18/trump-executive-order-psychedelics-joe-rogan/89676816007/
Reuters Trump signs order to accelerate access to psychedelic drug treatments https://www.reuters.com/world/trump-announces-reforms-accelerate-access-psychedelic-drug-treatments-2026-04-18/
Bloomberg Trump Signs Order on Psychedelics to Ease FDA Restrictions https://www.bloomberg.com/news/articles/2026-04-18/trump-signs-order-easing-restrictions-on-psychedelic-drugs
The Wall Street Journal How Joe Rogan Convinced Trump to Fast-Track Review of Psychedelic Drugs https://www.wsj.com/politics/policy/how-joe-rogan-convinced-trump-to-fast-track-review-of-psychedelic-drugs-3618fd73

From Toad "Venom" to Potential Antidepressant

https://www.psychologytoday.com/us/blog/addiction-outlook/202604/from-toad-venom-to-potential-antidepressant

AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs

https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response

66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohorts
Durable responses observed at Day 85: 83% (5/6) (10 mg) and 66.7% (4/6) (12 mg)
BPL-003 received FDA Breakthrough Therapy Designation in October 2025
Phase 3 initiation on track for Q2 2026

https://clinicaltrials.gov/study/NCT05660642

https://link.springer.com/article/10.1007/s40263-025-01250-z

Complete biosynthesis of psychedelic tryptamines from three kingdoms in plants

https://www.science.org/doi/10.1126/sciadv.aeb3034

This paper is not about discovering new psychedelics. It is about controlling how they are made. The researchers produced DMT, psilocin, psilocybin, bufotenin, and 5-MeO-DMT in a plant system by rebuilding the full biosynthetic pathway.

GOP Senator To File Bill Promoting Psychedelics Research And Treatment For Veterans

https://www.marijuanamoment.net/gop-senator-to-file-bill-promoting-psychedelics-research-and-treatment-for-veterans/

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst

https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-joins-3-trillion-crsp-index-and-sp-benchmark-indices

BPL-003 Nasal Spray Shows Quick and Enduring Effect in Treatment-Resistant Depression

https://www.psychiatrictimes.com/view/bpl-003-nasal-spray-shows-quick-and-enduring-effect-in-treatment-resistant-depression

Looking to hit 3.75 today

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation

https://ir.ataibeckley.com/news-releases/news-release-details/bpl-003-demonstrates-rapid-and-durable-antidepressant-effects

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression

https://journals.sagepub.com/doi/10.1177/02698811261420087

Wow

exciting here... wish there were more eyes

https://ir.ataibeckley.com/news-releases/news-release-details/bpl-003-phase-3-program-initiation-track-q2-2026-following

pushing past 4.00 today I thinks!

Wonderful day here.

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA DecisionsMarch 9, 2026 10:50 AM
PR Newswire (US)

Issued on behalf of Cybin D/B/A Helus PharmaUSANewsGroup.com News CommentaryVANCOUVER, BC, March 9, 2026 /PRNewswire/ -- The central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials and regulatory milestones accumulate1. The Drug Enforcement Administration raised its 2026 production quotas for controlled research compounds by 67%, reflecting expanding clinical trial activity across the therapeutics landscape2. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ: HELP), Compass Pathways (NASDAQ: CMPS), AtaiBeckley (NASDAQ: ATAI), Definium Therapeutics (NASDAQ: DFTX), and GH Research (NASDAQ: GHRS).  The World Health Organization estimates that depression and anxiety cost the global economy more than $1 trillion annually in lost productivity3. Treatment-resistant depression alone affects roughly 30% of patients diagnosed with major depressive disorder, fueling demand for novel mechanisms that can deliver rapid, durable therapeutic responses where traditional antidepressants have failed4. The pipeline is moving to meet it, and pharmaceutical capital is following.Helus Pharma™ (NASDAQ: HELP) is a clinical-stage pharmaceutical company developing novel serotonergic agonists for serious mental health conditions, including major depressive disorder and generalized anxiety disorder.Helus announced topline results from a Phase 2 signal detection study evaluating HLP004 as a potential adjunctive treatment for adults with moderate-to-severe generalized anxiety disorder who remained symptomatic despite ongoing standard-of-care antidepressant therapy. GAD affects more than 20 million adults in the United States, and no adjunctive pharmacologic treatment for the condition has ever been approved.In the study, 36 patients were randomized to HLP004 20 mg or 2 mg and received two intramuscular doses three weeks apart. Patients receiving 20 mg adjunctive to standard of care achieved a mean HAM-A reduction of 10.4 points (p

Curious how today performs with the rumors swirling.

ATAI Exploring $2B+ Deal for Psychedelic Depression Drug (Bloomberg Summary + Context)

A new Bloomberg report says **Atai Life Sciences’ joint venture AtaiBeckley is exploring strategic options for its lead psychedelic depression therapy BPL-003, including a sale or large pharmaceutical partnership potentially valued at $2B+.

According to people familiar with the discussions, the company has hired Jefferies Financial Group and JPMorgan Chase to run the process and approach potential pharma partners. The drug recently received FDA clearance to enter Phase 3 clinical trials for treatment-resistant depression.

https://www.bloomberg.com/news/articles/2026-03-07/ataibeckley-is-said-to-explore-options-for-main-psychedelic-drug?leadSource=reddit_wall

Some key details from the report:

BPL-003 is a nasal spray psychedelic therapy designed for rapid treatment of severe depression.

Over 20 million adults in the U.S. suffer from major depression, and roughly 30% don’t respond to existing treatments.

A deal could include co-development, where a large pharma partner helps fund Phase 3 trials and commercialization in exchange for revenue sharing.

Other options include royalty licensing or an outright asset sale.

The article notes that large pharma interest in psychedelic-style antidepressants has grown significantly since **Johnson & Johnson turned its ketamine-based drug Spravato into a multi-billion-dollar treatment for resistant depression.

Importantly, ATAI’s entire market cap is currently around $1.2B, meaning the company is reportedly seeking a partnership value greater than its current valuation for just one drug asset.

Why Partnerships Like This Matter for Small Biotech Stocks

In biotech, a large pharma partnership can completely change a company’s trajectory. These deals typically:

Fund expensive Phase 3 trials

Validate the science in the eyes of investors

Reduce dilution risk

Provide global commercialization capabilities

Because of this, biotech stocks sometimes reprice dramatically after partnerships or licensing deals.

Examples of Small Biotech Companies That Exploded After Partnerships

Here are several well-known examples where major partnerships helped trigger massive stock moves.

BioNTech

Before COVID vaccines existed, **BioNTech signed major collaborations with big pharma including Pfizer and Bristol Myers Squibb.

Stock performance:

2019 IPO price: about $13

2021 peak: about $400

➡ roughly 30× return

Large pharma partnerships helped validate the company’s mRNA platform technology long before the vaccine success.

Arrowhead Pharmaceuticals

RNA drug developer **Arrowhead Pharmaceuticals signed a major licensing agreement with Novartis worth up to $2B in milestones.

Stock performance:

2016: around $2–3

2021 peak: roughly $90

➡ about 30×

The partnership signaled that RNA interference drugs were commercially viable.

Exelixis

Cancer drug developer **Exelixis partnered with Bristol Myers Squibb and others to develop its drug cabozantinib.

Stock performance:

2012: roughly $1–2

2018 peak: around $30

➡ roughly 15×

Partnership funding helped the company finish development and bring a blockbuster cancer drug to market.

Moderna

Before its COVID vaccine success, **Moderna signed multi-billion-dollar research partnerships with Merck & Co. and AstraZeneca.

Stock performance:

2018 IPO: about $23

2021 peak: about $450

➡ roughly 20×

The partnerships validated the mRNA therapeutic platform years before commercialization.

Why This Could Be Important for Psychedelic Biotech

If a major pharmaceutical company partners with ATAI on BPL-003, it would likely signal that psychedelic-derived treatments for depression are entering mainstream pharma development.

That kind of validation could affect not just ATAI but the entire psychedelic biotech sector, especially companies working on:

treatment-resistant depression

rapid-acting antidepressants

next-generation psychedelic compounds

Bottom Line

The Bloomberg report suggests big pharma interest may be emerging around ATAI’s lead psychedelic depression drug.

If the company secures a major partnership near the $2B level, it would represent:

validation of the therapy

funding for Phase 3 trials

potential repricing of ATAI relative to its current market cap.

For investors in early-stage biotech — especially psychedelic drug developers — deals like this can sometimes become major inflection points for long-term stock performance.

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
March 3, 2026

Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosing
Phase 3 program initiation remains on track for Q2 2026
BPL-003 was previously granted Breakthrough Therapy designation by the FDA for treatment-resistant depression
Virtual Investor Day scheduled on March 6, 2026, to provide further detail on the BPL-003 Phase 3 clinical strategy

https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-announces-successful-end-phase-2-meeting-bpl-003